LifeMine draws $263M to advance calcineurin inhibitor for transplant rejection: Venture Report

LifeMine, a Mass.-based company using fungal genomics to discover new therapies, topped the week’s venture rounds with $263 million raised to advance a long-acting calcineurin activation inhibitor designed to prevent organ transplant rejection.

Nine-year-old LifeMine Therapeutics Inc. digitally mines annotated genomes from its repository of fungal isolates to identify compounds predicted to have potent activity against therapeutic targets. ...